The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world clinical outcomes among patients with non-squamous advanced non-small cell lung cancer (aNSCLC) treated with docetaxel-based regimens post initial standard of care (SOC) in the United States.
 
Ruchit Shah
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
Research Funding - Daiichi Sankyo
 
Furaha Kariburyo-Yay
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Daiichi Sankyo/UCB Japan (Inst); Incyte (Inst); Merck (Inst); Regeneron (Inst)
 
Jon Apple
Employment - AstraZeneca
Research Funding - AstraZeneca
 
Lincy S. Lal
Employment - ConcertAI; Optum/UnitedHealth Group
Stock and Other Ownership Interests - Concertai
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo/UCB Japan (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Oncology (Inst); Kyowa Kirin International (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst); Sandoz (Inst); Teva (Inst)
 
Vincent Miller
Employment - EQRx (I)
Leadership - Revolution Medicines (I)
Stock and Other Ownership Interests - EQRx (I)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Sandoz (Inst); Teva (Inst); Teva (Inst)
 
Joshua E. Reuss
Honoraria - Merck
Consulting or Advisory Role - Abbvie; Arcus Biosciences; AstraZeneca; Bristol-Myers Squibb; Catalym; Daiichi Sankyo; Gilead Sciences; Guardant Health; Janssen; Novocure; Seagen; Summit Therapeutics
Research Funding - Exelixis (Inst); Genentech/Roche (Inst); Nuvalent, Inc. (Inst); Verastem (Inst)